A model of quiescent tumour microregions for evaluating multicellular resistance to chemotherapeutic drugs by Mellor, H R et al.
A model of quiescent tumour microregions for evaluating
multicellular resistance to chemotherapeutic drugs
HR Mellor
1, DJP Ferguson
2 and R Callaghan*,1
1Oxford Drug Resistance Group, Nuffield Department of Clinical Laboratory Sciences, John Radcliffe Hospital, University of Oxford, Oxford OX3 9DU,
UK,
2Ultrastructural Morphology Group, Nuffield Department of Clinical Laboratory Sciences, John Radcliffe Hospital, University of Oxford, Oxford OX3
9DU, UK
The quiescent cell population of tumours poses a barrier to the success of many cancer therapies. Most chemotherapeutic drugs
target proliferating cells, but the growth fraction of many tumours is low. Based on the multicellular tumour spheroid model, a system
was developed using human colon adenocarcinoma (DLD-1) cells to mimic the microenvironment of quiescent microregions of solid
tumours. The quiescent tumour spheroids (TS
Q) showed decreased expression of the proliferation marker Ki-67 and increased
expression of the quiescence marker p27
kip1 compared to proliferating spheroids (TS
P). The quiescent status of the TS
Q was
confirmed by long-term growth assessment. The quiescence was completely reversible demonstrating that the TS
Q retained the
ability to proliferate and morphological assessment by light microscopy confirmed the absence of significant apoptosis. When the
efficacy of widely used chemotherapeutic drugs was determined, vinblastine, doxorubicin, cisplatin and 5-fluorouracil (5-FU) all
produced significant cell death in the TS
P. However, while still effective, the potencies of doxorubicin and cisplatin were significantly
reduced in TS
Q. In contrast, 5-FU and vinblastine did not produce cell death in the TS
Q. In summary, TS
Q show considerable
resistance to a panel of established chemotherapeutic agents and represent a useful model for evaluating the efficacy of drugs and
other cancer therapies in quiescent tumours.
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In many tumours, the actively dividing cells account for only a
small proportion of the total, with the remainder of the cells being
in a quiescent state (Q-cells) (Jackson, 1989). For particularly
slow growing tumours (e.g. prostatic), a mean growth fraction
of o3% has been reported (Gallee et al, 1989; Berges et al,
1995). The quiescent cells within the tumour are viable but in a
reversible state of growth arrest (Desoize and Jardillier, 2000).
The mechanism behind the development of an intratumoural
population of Q-cells remains unclear, but it may be a consequence
of multiple microenvironmental factors, which result from
the abnormal/inadequate vasculature often found within solid
tumours (Brown and Giaccia, 1998). For example, hypoxia has
been shown to evoke cell cycle arrest via the cyclin-dependent
kinase (CDK) inhibitor p27
kip1 (Gardner et al, 2001).
The relative expression levels of cellular proliferation (e.g.
Ki-67) and quiescence (e.g. p27
kip1) markers are valuable in
determining the aggressiveness of tumours and therefore for
predicting prognosis. A high proportion of Ki-67-positive cells in a
tumour is indicative of a poor prognosis (Scholzen and Gerdes,
2000). Similarly, patients with tumours expressing low levels of
p27
kip1 have a poorer prognosis than those whose tumours have
high p27
kip1 expression. Such correlations have been shown for
many different human cancers (Blain et al, 2003). However,
aggressive tumours with a high proportion of Ki-67-positive cells,
despite imparting a poorer prognosis upon the patient, usually
respond well to chemotherapy (Kamoi et al, 2001; Petit et al, 2004).
The selectivity of chemotherapeutic agents for killing prolifera-
ting cells (P-cells) over Q-cells has been demonstrated for many
classes of drugs in cell monolayers (Valeriote and van Putten, 1975;
Siu et al, 1999) and in the solid tumours of patients (Remvikos
et al, 1993; Hietanen et al, 1995). In addition to their inherent
chemoresistance, the inadequate vascularisation in tumour regions
occupied by Q-cells leads to low local concentrations of drugs. As
a consequence, the large Q-cell population of many human
carcinomas (e.g. colon carcinoma, non-small-cell lung carcinoma)
contributes to these tumours being refractory to many chemo-
therapy regimens (Jackson, 1989).
The insensitivity of Q-cells to chemotherapeutic drugs also
contributes to the additional problem of regrowth resistance,
through recruitment of the surviving Q-cells to the P-fraction after
drug treatment (Brown and Giaccia, 1998; Siemann, 1998; Desoize
and Jardillier, 2000). The low growth fraction of many tumours
leads to the requirement for multiple repeated drug treatments
over a prolonged time period (Shah and Schwartz, 2000). Finally,
certain chemotherapeutic drugs can themselves induce quiescence
in tumour cells (Carroll et al, 2003), rendering these cells
refractory to the effects of further drug intervention.
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sTherefore, an important question is how to treat those more
indolent solid tumours that are chemoresistant due to a Q-cell
population? Even for emerging cancer treatments such as gene
therapy, tumour Q-cells pose a significant barrier to successful
treatment. For example, the use of many retroviral vectors is
significantly hampered by the dependence on host cell prolifera-
tion for viral replication (Patton et al, 2004). It is of paramount
importance that we gain a greater insight into the efficacy of
currently available therapies for killing tumour Q-cells and to
develop novel drugs or therapeutic approaches that are more
selective for this cell population.
In order to screen and evaluate chemotherapies and other
therapeutic approaches, a suitable model system is required that is
representative of the quiescent regions of solid tumours. Adapted
monolayer cultures have been previously used to model popula-
tions of quiescent tumour cells (Phillips and Clayton, 1997;
Horiatis et al, 2004). However, monolayers do not pose the barrier
to drug penetration or provide many of the microenvironmental
influences found in solid tumours and 3D cultures (Desoize and
Jardillier, 2000). The multicellular tumour spheroid (MCTS) model
(Inch et al, 1970; Sutherland et al, 1971; Hamilton, 1998) involves
the culturing of cancer cell lines as 3D structures. In the absence
of a suitable tissue culture system, we developed and evaluated a
TS model of quiescent tumour microregions (TS
Q) and compared
them to proliferating spheroids (TS
P). We chose to establish the
TS using a DLD-1 human colon adenocarcinoma cell line as the
mean doubling time of cancer of the colon is 90 weeks (Slingerland
and Tannock, 1998) and this disease is synonymous with a poor
chemotherapeutic response. To evaluate the usefulness of this new
system, immunohistochemical detection of the proliferation
marker Ki-67 and the quiescence marker p27
kip1 was performed
to assess the localisation of P- and Q-cells within the TS. The long-
term growth characteristics of both types of TS were measured and
the viability of the TS
Q after long-term quiescence was studied.
In order to compare drug resistance profiles in the TS
P and TS
Q,
a novel method for quantifying cells within the spheroid mass was
developed and utilised to test a series of commonly used
chemotherapeutic agents. We chose to study the long-term
response to drug treatment as discrepancies between short- and
long-term responses have previously been observed when compar-
ing the effects of drugs in P- and Q-cells (Siu et al, 1999).
MATERIALS AND METHODS
Materials
RPMI-1640 medium (with Glutamax I and 25mM HEPES), foetal
bovine serum (heat inactivated), penicillin/streptomycin solution
and trypsin-EDTA were purchased from Life Technologies Ltd,
UK. Methylene blue and fatty acid-free BSA were purchased from
Sigma, UK. For the immunohistochemistry, Ki-67 and p27
kip1
mouse anti-human monoclonal antibodies were obtained from
DakoCytomation, UK. Mach-2 polymer-HRP conjugate and
peroxidazed 1 were from BioCarta, UK. Haematoxylin and
aquamount were obtained from BDH Laboratory Supplies, UK.
Vinblastine sulphate, doxorubicin hydrochloride and 5-fluoro-
uracil (5-FU) were purchased from Sigma. Cisplatin was obtained
from Professor Trevor W Hambley (University of Sydney,
Australia).
Cell lines, culture and TS production
DLD-1 human colon adenocarcinoma cells were obtained from
Dr Roger Phillips (University of Bradford, UK) and were grown as
monolayers in RPMI-1640 medium (with Glutamax I and 25mM
HEPES) supplemented with 10% (vv
 1) fetal bovine serum and
penicillin (100IUml
 1)/streptomycin (100mgml
 1). For most
experiments, TS of DLD-1 cells were grown in spinner flasks
(Techne, UK). A mother dish was prepared by coating the base
of a T75 cm
2 cell culture flask with 20ml of 0.75% (wv
 1) agarose
prepared in medium without serum. Exponentially growing DLD-1
cells were added in 20ml of medium at a density of 1.5 10
6
cellsml
 1 and the flask was left stationary for 24h (371C, 5% CO2).
Any large-cell aggregates were removed by gravity sedimentation
and the remaining small aggregates were transferred to a 500ml
spinner culture flask and made to a total volume of 100ml of
serum containing medium. The spinner flask was then placed on
a stirrer (Techne MCS-1045) at 371C, 5% CO2 for an initial period
of 3 days to allow the TS
P to form. To generate TS
Q, the TS
P were
washed with PBS and fresh medium containing 0.1% fatty acid-free
BSA instead of 10% FCS was added. For continuous culturing of
TS
P and TS
Q, the appropriate medium was refreshed (50ml) every
other day.
TS growth curves
In order to monitor growth of TS
Q and TS
P, TS were removed from
the spinner flask to a Petri dish in a small volume of medium. The
diameter of TS (nC20) was measured daily, at the same time of
day, and after measurements had been taken, the TS were replaced
in the spinner flask. A graduated calibrated microscope eyepiece
graticule (Pyser-SGI, UK) was used to measure TS diameter. TS
diameter was converted into micrometers (mm), which allowed
calculation of TS volume (mm
3). Growth curves for TS represent
the mean7s.e.m. of three independent experiments.
Routine histological procedures
TS were harvested, washed in PBS and fixed in neutral-buffered
formalin (pH 7.0). The TS were transferred to small plastic casting
moulds for embedding, allowed to settle and the formalin
removed. The moulds were filled with melted 2% (wv
 1) agarose
in 4% (vv
 1) formaldehyde. The agarose was allowed to set on
ice before being removed from the mould and placed in a tissue
cassette, which was routinely processed (Histopathology Depart-
ment, John Radcliffe Hospital, Oxford, UK). The processed,
agarose-embedded, TS were embedded in paraffin wax and 5mm
sections were cut.
Proliferation status of TS
P and TS
Q: Ki-67 and p27
kip1
TS sections (day 12) were completely dewaxed and rehydrated
with PBS, placed in 50mM Tris/200mM EDTA buffer, pH 9.0, and
antigen retrieval was carried out in a Decloaking Chamber Pro
(Biocarta, UK) at 1201C for 30s. Sections were washed with PBS
and incubated in a humidified chamber (251C) with peroxidazed
for 10min to inhibit endogenous peroxidase activity. After
washing the sections with PBS, the primary monoclonal antibody
(mouse anti-human), Ki-67 (1:100 in PBS) or p27
kip1 (1:50 in
PBS), was added for 45min at RT. Mach-2 goat-anti-mouse HRP
conjugate was added for 45min and detection was achieved using
DAB substrate chromagen. Sections were counterstained with
haematoxylin and mounted with aquamount.
Calibration of cell number in TS by methylene blue
staining
Freshly trypsinised DLD-1 cells taken from exponentially growing
cultures were overlaid on solid agarose base-coats at densities
ranging from 1 10
3 to 3 10
4 cells in 100ml medium. The cells
were kept stationary for 24h (371,5 %C O 2) after which the plates
were transferred to a Titramax 100 (Heidolph Instruments,
Germany) and shaken at 300r.p.m. for a further 24h (371C, 5%
CO2) to allow TS to form. The TS were moved to a new ‘uncoated’
well in a 48-well plate, 500ml of fresh medium was added and TS
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the medium was aspirated and replaced with 200mlo f5 g l
 1
methylene blue in methanol, for 30min, to fix and stain the cells.
The wells were washed five times with tap water to remove excess
dye and the plates were allowed to dry overnight (251C). The
stained TS
P were solubilised with 200ml of 2% SDS by shaking on
a Titramax 100 at 300r.p.m. for 24h (251C). A 100ml aliquot was
taken from each well and placed in the well of a 96-well plate and
the absorbance was measured at 650nm in a Spectra Max 250
microplate reader (Molecular Devices, UK).
Drug cytotoxicity measurements in TS
Proliferating tumour spheroids were grown as described above and
on day 6 (when they have no inherent Q-cells) were transferred
in 100ml of fresh medium to 96-well tissue culture plates, which
had previously been given a 100ml base-coat of 0.75% (wv
 1)
agarose (prepared in RPMI-1640 medium). Drugs were prepared
in medium at twice the desired concentration to give a final
concentration range of 1nM to 316mM (up to 1mM for 5-FU) and
100ml aliquots were added to each well. After the 16h incubation,
the TS
P were moved to a new ‘uncoated’ well in a 48-well plate
and 500ml of fresh medium added. The TS
P were incubated for a
further 6-day recovery period. After this time, the methylene blue
assay was performed as described above.
The TS
Q were generated from TS
P at 6 days growth by switching
the medium to serum-free as described above and all subsequent
culturing of TS
Q was performed in this medium. The drug
exposure and recovery protocol used for TS
P was applied to the
TS
Q; however, a slightly modified staining procedure was applied
due to nonadherent nature of the TS
Q. After the 6-day recovery
period, TS
Q were transferred to the wells of a round-bottomed
96-well plate, the medium was aspirated and 200ml of 5gl
 1
methylene blue in methanol was added to each well for 30min. The
dye was aspirated, and the fixed spheroids were washed three times
with 250ml of tap water. The solubilisation procedure and
absorbance measurements were performed as above.
Morphological evaluation of TS
For morphological examination and comparison of the different
TS models, TS
Q at the end of the growth study (i.e. day 25) and
TS
P of equivalent size (approximately day 8) were used. For
drug-treated samples, day 6 TS
P or TS
Q were transferred to
agarose-coated 96-well plates and exposed to vinblastine (3mM),
doxorubicin (3mM) or cisplatin (30mM) for 48h. This period of
exposure to the above concentrations of these drugs had
previously been shown to result in morphologically observable
cytotoxicity in proliferating TS (Hall et al, 2004). TS were washed
in PBS and fixed in 4% glutaraldehyde in 0.1 M phosphate buffer.
Samples were postfixed in osmium tetroxide, dehydrated in
ethanol, treated with propylene oxide and embedded in Spurr’s
epoxy resin. Sections were cut at 1mm thick and were stained with
Azure A. Morphological features were identified by light micro-
scopy. The number of apoptotic and mitotic cells per spheroid
section was counted.
Data analysis
Data analysis was performed using GraphPad Prismt software.
Spheroid growth data were fitted with an exponential growth curve
using the equation Y¼Ae
KX, where Y is the spheroid volume
(mm
3) and X is time (days). Y starts at A and increases
geometrically with a doubling time equal to 0.6932/K. The
doubling times obtained from the curves were compared based
on 95% confidence intervals using one-way ANOVA and Tukey’s
post-test. Drug cytotoxicity in TS was quantified using nonlinear
regression as described in (Hall et al, 2004).
RESULTS
TS markers of proliferation and quiescence
Serum withdrawal is a well-established method of inducing
quiescence in cultured cell lines and has previously been used to
induce quiescence in DLD-1 cells (Shida et al, 2003). However, as
far as we are aware, this approach has not previously been applied
to TS. To characterise the proliferative changes occurring within
the TS tissue, spheroids were immunostained for the proliferation
marker Ki-67 and the quiescence marker p27
kip1.
Initial investigations examined the effect of serum withdrawal
on Ki-67 expression in the TS. Prior to serum withdrawal (t¼0h),
a large proportion of the cells within the tissue were Ki-67-positive,
particularly those at the periphery, with a small nonproliferating
population located at the centre of the TS (Figure 1), an expected
feature of TS of intermediate size (day 12). After 24h in serum-free
medium, Ki-67 expression was relatively unchanged; however,
by 48h a dramatic decrease was evident. Moreover, the location of
the few Ki-67-positive cells was no longer biased to the periphery.
A further decrease in expression was seen after 72h, by which
point only a residual number of cells appeared to be proliferating
(Figure 1).
In addition to the dramatic decrease observed in the number of
Ki-67-positive cells within the TS, a concurrent increase in p27
kip1-
positive cells was seen during the 72h period of serum starvation.
Initially (t¼0h), the central region of the TS contained a number
of p27
kip1-positive cells (Figure 1), consistent with the absence of
Ki-67 staining in this region. However, in contrast to the dramatic
decrease in KI-67 that occurred between 24 and 48h, p27
kip1
expression increased gradually over the 72h period. At 72h,
almost every cell was found to be p27
kip1-positive, consistent with
the almost complete absence of Ki-67 expression at this time
(Figure 1). The change in Ki-67/p27
kip1 expression was reversible,
over a 72h period, upon readministration of serum-containing
medium (data not shown).
Growth curves of TS
Q and TS
P
The growth rates of the quiescent spheroids (TS
Q) were compared
with those of actively proliferating spheroids (TS
P) to further
characterise the model. As shown in Figure 2, the effect of
culturing TS in serum-free medium was dramatic. From day 3,
when the medium was changed, the curves for the TS
P and TS
Q
diverged. The TS
P displayed sustained, exponential growth, which
continued up to day 17 when the spheroid volume was B0.28mm
3
(dC800mm). At this point, the spheroids collapsed, most likely
due to the large area of central necrosis that the TS
P developed by
this late stage. In comparison, the TS
Q showed minimal growth on
a day-to-day basis, although an increase in spheroidal volume
(0.00770.002 to 0.03670.008mm
3) was evident over the 25-day
observation period (Figure 2). This small volume increase
indicates that a small proportion of cells were capable of
proliferation even in the absence of serum. The growth differences
between the two types of TS is highlighted by the fact that between
day 3 and day 17, the TS
P demonstrated a 48-fold increase in
volume compared to only a 2.5-fold increase for the TS
Q.
The aim of developing the TS
Q model was to enable examination
of the sensitivity of quiescent tumour microregions to chemo-
therapeutic agents. In order to achieve this, it was important to
establish that the serum-free medium used to generate the model
did not have any deleterious effects on the viability of cells within
the TS
Q, other than to restrict cell division. Therefore, the
reversibility of the serum withdrawal was checked by replacing
the TS
Q growth medium with serum-replete. This was carried out
on day 10 and again on day 15 and the ability of the TS
Q to
proliferate was assessed. The addition of serum to the culture
medium rapidly returned the TS
Q to a proliferative state (Figure 2).
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Q switched at day 10 (open
triangles) or even later, at day 15 (closed triangles). Once
proliferation had been initiated, these TS followed the same
pattern of growth as TS
P. No statistically significant difference
was observed in the rate of proliferation between the TS
P cultured
in serum throughout from those that had been switched from a
quiescent to a proliferative state. A significant difference (Po0.01)
was found between the doubling time of the TS
Q (11.772.1 days)
and each of the TS
P groups (3.070.1 days).
Efficacy of chemotherapeutic drugs in TS
To assess the cytotoxicity of various chemotherapeutic agents in
TS
Q and TS
P, we developed a modified version of the methylene
blue TS outgrowth assay. The original assay was unsuitable for
the nonproliferating TS
Q due to the lack of cellular outgrowth.
Consequently, the assay was modified to quantify the amount of
dye associated with the TS after staining. This provided a reliable,
quantitative measure of total TS cell number. The linearity of the
assay was checked by generating TS with a wide range of sizes
(1 10
3 to 3 10
4 cells). A linear relationship was found between
cell number and methylene blue absorbance for TS over the range
of sizes tested (Figure 3), and therefore the assay was a way of
assessing drug cytotoxicity in the TS.
TS of B1 10
4 cells (day 6 of spinner flask culture) were chosen
for the cytotoxicity assays as these TS consisted entirely of
proliferating cells and were within the linear range of sizes defined
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Figure 2 Growth curves for TS and reversibility of long-term
quiescence. To generate TS
Q (black circles), 3 days after seeding the
spinner flask (day 3) TS
P (open circles) were washed with PBS and fresh
medium was added containing 0.1% fatty acid-free BSA instead of 10% FCS.
To assess the reversibility of the growth arrest evoked by serum
withdrawal, the TS
Q growth medium was switched back to serum-
containing day 10 (open triangles) and again on day 15 (closed triangles).
For continuous culturing of TS
P and TS
Q, the appropriate medium was
refreshed (50ml) every other day. In order to monitor growth of TS
Q and
TS
P, TS were removed from the spinner flask to a Petri dish in a small
volume of medium. The diameter of TS (nC20) was measured daily and
was used to calculate TS volume (mm
3). Growth curves represent the
mean7s.e.m. of three independent experiments.
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Figure 3 Standard curve for methylene blue staining against TS cell
number. To ensure methylene blue staining was representative of the total
number of cells present in a 3D TS, the assay was performed on TS of
defined cell number from 1 10
3 to 3 10
4 cells. Staining, solubilisation
and absorbance measurements were carried out and the standard curve of
absorbance against TS cell number was plotted.
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Figure 1 Time course of serum withdrawal on expression of Ki-67 and
p27
kip1 in TS. The TS growth medium was replaced with fresh medium
containing 0.1% fatty acid-free BSA instead of 10% FCS. TS were harvested
at various times over a period of 72h and were fixed in formalin, routinely
processed and embedded in paraffin wax. Immunohistochemistry was
performed on sections (5mm) to detect the proliferation marker Ki-67 and
the quiescence marker p27
kip1. Sections were counterstained with
haematoxylin and mounted with aquamount. The scale bar corresponds
to 100mm.
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sby the standard curve (Figure 3). This allowed for substantial
drug-induced cell loss to be measured. A 16h drug exposure time
was employed for the cytotoxicity assays, followed by a 6-day
‘recovery’ period designed to allow any cytotoxic effects imparted
by the drugs to be fully realised in the TS
P and TS
Q.
The drugs chosen were selected on the basis of their different
mechanisms of action and due to their established and widespread
use in the clinic. For all of the chemotherapeutic agents tested,
the potency in the TS
Q was significantly lower than that observed
in the TS
P (Table 1). All of the drugs demonstrated considerable
cytotoxicity in the TS
P, vinblastine and doxorubicin being
equipotent with an IC50 of B1mM. Cisplatin (IC50 3.371.2mM)
and 5-FU (IC50 2578mM) also produced significant inhibition of
TS
P growth, although their potencies were reduced. The extent of
cell kill at the maximum drug concentration was high for all of the
drugs (485% see Table 1), demonstrating that the majority of cells
within the TS
P were drug-sensitive. Despite the high concentra-
tions of drugs used (up to 316mM except 5-FU (1mM)), the TS
Q
were mostly insensitive to the effects of two of the agents, the vinca
alkaloid vinblastine and the antimetabolite 5-FU. The mean extent
of cell kill was 34712 and 11711% for the respective compounds.
As a result of the lack of cytotoxicity, no meaningful IC50 was
achievable for these compounds (Table 1).
In contrast, both doxorubicin and cisplatin displayed consider-
able cytotoxicity in the TS
Q. The potency of doxorubicin in the TS
Q
(1375mM) was 16-fold lower than that displayed in the TS
P and
the potency of cisplatin in the TS
Q (84730mM) was 38-fold lower
than that displayed in the TS
P. As observed in the TS
P, the majority
of the TS
Q cells were sensitive to the effects of doxorubicin and
cisplatin with a maximum cell kill of 81710 and 80712%,
respectively.
Morphological analysis of TS
Morphological findings in the TS
P and TS
Q supported the previous
experimental observations. A number of mitotic cells (mean 5.9
per TS, Figure 4E) were observed in the outer regions of the TS
P
(Figure 4A), but few (mean 0.33 per TS, Figure 4E) were observed
in the TS
Q (Figure 4B). This is consistent with the change in
expression of proliferation markers (Figure 1) and the difference in
growth of the TS
Q compared with the TS
P (Figure 2). Long-term
culturing of TS
Q in 0.1% BSA (day 25) did not lead to an increase
in the number of apoptotic bodies (Figure 4B) (mean 0.33 per TS
section, Figure 4E) compared to the TS
P (mean 0.71 per TS section,
Figure 4E). This is consistent with growth arrest due to a decrease
in mitosis and is not associated with increased apoptosis. It is
also consistent with the finding that the quiescent status of the TS
Q
is fully reversible to TS
P with no decrease in the rate of growth
(Figure 2). There appeared to be some deposition of glycogen in
the TS
Q, previously shown to be associated with decreased cell
division rates in human colon carcinoma cell lines (Rousset et al,
1980), and therefore consistent with long-term culturing of
DLD-1 TS
Q. Cisplatin-treated TS
P contained a number of apoptotic
bodies (Figure 4C). Although there were some apoptotic bodies in
the cisplatin-treated TS
Q (Figure 4F), there were often none in a
particular field (Figure 4D). For all of the chemotherapeutic drugs,
a reduced level of apoptosis was observed in the TS
Q compared to
the TS
P (Figure 4F). This is consistent with the cytotoxicity assays
where a decrease in the potencies of all of the drugs tested was
observed in the TS
Q relative to the TS
P (Table 1).
DISCUSSION
In general, slowly growing tumours tend to be less drug-sensitive
than rapidly growing tumours. Of the various cytokinetic factors
that contribute to tumours having slow growth rates (e.g. long
cycle times, high cell loss, Q-cells) (Riedel, 2002), modelling
studies suggest that the presence of a large Q-cell compartment has
the most serious implications for chemotherapy (Jackson, 1989).
Most proliferation models are based on cell monolayers (Horiatis
et al, 2004), but it is well established that for many chemo-
therapeutic drugs, a solid tissue environment affords an increased
level of drug resistance (Desoize and Jardillier, 2000; Hall et al,
2004) called multicellular resistance. It is therefore of paramount
importance in the evaluation of current and future therapies that a
suitable system is developed to better represent the multicellular
quiescent microregions in solid tumours.
Serum withdrawal is an established way of evoking growth arrest
in proliferating cells, and although this approach has been used for
DLD-1 cells (Shida et al, 2003), it has not previously been applied
to TS. Ki-67 is a nuclear protein present during all active phases of
the cell cycle in both normal and cancerous cells. It is expressed in
P-cells but not Q-cells and is therefore a useful marker for cellular
proliferation (Endl and Gerdes, 2000; Scholzen and Gerdes, 2000).
We observed that after 72h in serum-free medium, very few cells
within the TS expressed the protein and were therefore no longer
proliferating. To observe the switch from proliferating to quiescent
cells within the TS, immunostaining for p27
kip1 was performed.
The levels of this protein are increased in quiescent cells (Lloyd
et al, 1999) and constitutive expression in cultured cells leads
to arrest in G1 phase of the cell cycle (Toyoshima and Hunter,
1994). In response to serum withdrawal, we observed a dramatic
increased in expression of p27
kip1 that was seen throughout the
TS by 72h. This was consistent with the Ki-67 staining results and
demonstrated that the cells had entered a quiescent state.
In addition to displaying markers of cellular quiescence, the
TS
Q showed minimal signs of growth over the 25-day measurement
period. However, the spheroids retained the capacity for
proliferation as was clear from the dramatic increase in TS size
Table 1 Efficacy of chemotherapeutic drugs in TS
TS
P TS
Q
Drug IC50 (lM) Extent of cell kill (% of total cells) IC50 (lM) Extent of cell kill (% of total cells)
Vinblastine 1.470.7 8875N o I C 50 at max conc. 34712
Doxorubicin 0.870.2 93751 3 75
a 81710
Cisplatin 3.371.2 100708 4 730
a 80712
5-FU 25788 8 74N o I C 50 at max conc. 11711
TS
P¼proliferating tumour spheroids; TS
Q¼quiescent tumour spheroids; 5-FU¼5-fluorouracil. TS
P and TS
Q were exposed to a range of concentrations of chemotherapeutic
drugs (1nM to 316mm (up to 1mM for 5-FU)) for 16h. The TS were incubated in drug-free medium for a further 6-day (recovery) period to allow the cytotoxic effects of the
drugs to be realised. After this time, the methylene blue assay was performed. The potency of the drug to elicit cytotoxicity was expressed as an IC50 value determined from
dose–response curves as described in the Materials and Methods. The extent of the cell kill in the TS was expressed as a percentage of control for the highest concentration of
drug tested. Six replicates were performed for each drug concentration with the values obtained from three or more independent observations being shown as mean7s.e.m.
aIndicates statistical significance (Po0.05).
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swhen they were exposed to serum-containing medium. This
proliferative potential retained by quiescent cells forms the basis
for the regrowth resistance that arises after chemotherapy or
ionising radiation treatments when these insensitive cells repopu-
late the tumour (Desoize and Jardillier, 2000). It was clear from
both the proliferative response of the TS
Q and the microscopy data
that there were no deleterious effects of serum withdrawal on the
TS
Q. This was an important factor in the use of the system for the
assessment of drug-induced cytotoxicity.
In order to test our model, we exposed the TS
Q and TS
P to
anticancer drugs with different mechanisms of action. All of the
drugs were less effective in the TS
Q relative to the TS
P, highlighting
the inherent drug resistance of these quiescent microregions. The
two phase-specific agents we studied, 5-FU (S phase) and
vinblastine (M phase), were both ineffective in the multicellular
environment of the TS
Q. The mechanism of action of the uracil
analogue 5-FU is through incorporation of its metabolites into
RNA and DNA and through thymidylate synthase inhibition
(Longley et al, 2003), which is required for DNA replication and
repair. The inability of 5-FU to exert any cytotxicity in the TS
Q
is consistent with the lack of replicating cells compared to the
TS
P. Vinblastine, along with vincristine, is a naturally occurring
member of vinca alkaloid class of anticancer drugs. It is an
antimitotic agent that blocks cells in metaphase through suppres-
sion of microtubule dynamics (Jordan and Wilson, 2004). The
selectivity of the drug for cells undergoing mitosis explains
why the nondividing TS
Q were unresponsive to vinblastine
administration.
The two phase-nonspecific agents, doxorubicin and cisplatin,
while showing less efficacy in the TS
Q, maintained a significant
cell kill. Cisplatin forms covalent adducts with DNA, the most
prevalent being the 1, 2-intrastrand crosslink (Zamble and
Lippard, 1995). The DNA adducts are detected by a range of
damage recognition proteins, which leads to apoptosis or DNA
repair and survival (Siddik, 2003). The relative sensitivities of
P- and Q-cells to the initial DNA–platinum adduct formation
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Figure 4 Effects of chemotherapeutic drug treatment on the morphology of TS. TS were fixed in 4% glutaraldehyde in 0.1 M phosphate buffer, postfixed
in osmium tetroxide, dehydrated in ethanol, treated with propylene oxide and embedded in Spurr’s epoxy resin. Sections were cut at 1mm thick and stained
with Azure A. Images are representative of the typical appearance. The scale bar represents 10mm. (A) Untreated TS
P showing a number of mitotic cells
(arrows). (B) Untreated TS
Q consisting of interphase cells with very few mitotic or apoptotic cells. (C)T S
P treated with cisplatin (3mM) for 48h showing a
number of apoptotic bodies (arrows). (D)T S
Q treated with cisplatin (3mM) for 48h showing little evidence of apoptosis. (E) The number of mitotic cells
(black bars) and apoptotic bodies (white bars) expressed as a mean per spheroid section for TS
P and TS
Q.( F) The number of apoptotic bodies in TS
P and
TS
Q treated with doxorubicin (black bars), vinblastine (white bars) and cisplatin (lined bars) expressed as a mean per spheroid section.
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sremains unclear. However, replication is required for
the formation of cisplatin-induced DNA double-strand breaks
(Kaina, 2003). In addition, Q-cells in solid tumours in vivo have
previously been shown to have greater DNA repair capacities than
the total cell population in response to cisplatin (Masunaga et al,
1999). Cell cycle arrest is often considered inhibitory to the
induction of cytotoxicity and is known to be important in enabling
the nucleotide excision repair machinery to remove cisplatin
adducts (Siddik, 2003). Therefore, the decreased sensitivity of the
TS
Q to cisplatin may be a result of the Q-cells having a greater
capacity and/or more time to repair the cisplatin-induced DNA
damage.
Doxorubicin displayed a decreased potency in the TS
Q
compared to the TS
P, indicating that the cytotoxic effects are only
partly proliferation-dependent. A previous study also observed
an increase in long-term survival and proliferation potential in
doxorubicin-treated Q-cells over P-cells (Siu et al, 1999). The
proliferation-independent cell death observed in the TS
Q could
result from one or more of the multiple activities of doxorubicin.
These include free radical generation, lipid peroxidation, DNA
adduct formation, interference with DNA unwinding and mem-
brane-mediated effects (Gewirtz, 1999; Minotti et al, 2004).
To overcome the problem of these chemoresistant quiescent
tumour cells, a greater understanding of the mechanisms
regulating proliferation in cancer cells and how these operate in
a multicellular tumour environment is required. One possible
approach to restore chemotherapeutic sensitivity may be to inhibit
temporarily the activity of p27
kip1 and therefore force the Q-cells
into the cycle prior to drug administration. The validity of this
approach has already been demonstrated in vitro by pretreating
TS with antisense oligonucleotides to p27
kip1. This resulted in
increased cellular proliferation and sensitised the tumour cells to
4-hydroperoxycyclophosphomide (St Croix et al, 1996). Any
approach should ideally be selective for the killing of tumour
Q-cells over the normal cells of the body, which are also mostly
quiescent.
In summary, we have described a new derivative of the MCTS
model that mimics quiescent microregions within solid tumours.
Like those solid tumours in the clinic with low proliferative
fractions, these TS
Q show considerable resistance to a panel of
established chemotherapeutic agents. The model described here
would not only be useful for initial drug screening but also for
assessing the long-term efficacy of drugs in quiescent tumour
microregions. For example, after exposure to a chemotherapeutic
drug, the TS
Q could be maintained in a quiescent state for a
defined period before being selectively returned to a proliferating
state. This would mimic the recruitment of Q-cells to the
proliferating fraction that occurs in solid tumours in vivo. Using
this approach will enable examination of the longevity of drug
damage in quiescent microregions and the factors influencing this
such as DNA repair capacity. This model may also be useful in
evaluating the penetration of viral/non-viral vectors in quiescent
tumour tissue and the subsequent protein expression.
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